Authors
Stern, Peter LBrown, Michael D
Stacey, Simon N
Kitchener, Henry C
Hampson, Ian N
Abdel-Hady, El-Said
Moore, James V
Affiliation
Department of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, M20 4BX, Manchester, UK.Issue Date
2000-10
Metadata
Show full item recordAbstract
BACKGROUND: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. OBJECTIVES: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. CONCLUSION: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia.Citation
Natural HPV immunity and vaccination strategies. 2000, 19 (1-2):57-66 J. Clin. Virol.Journal
Journal of Clinical VirologyPubMed ID
11091148Type
ArticleLanguage
enISSN
1386-6532Collections
Related articles
- Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
- Authors: Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL
- Issue date: 2003 Sep 15
- Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
- Authors: Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH
- Issue date: 2004 May 1
- Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment.
- Authors: Cornelison TL
- Issue date: 2000 Sep
- [Possibilities of vaccination against HPV infections in cervix carcinoma].
- Authors: Gissmann L
- Issue date: 2001 May
- Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia.
- Authors: Davidson EJ, Sehr P, Faulkner RL, Parish JL, Gaston K, Moore RA, Pawlita M, Kitchener HC, Stern PL
- Issue date: 2003 Aug